Long-term treatment with solriamfetol was associated with clinically meaningful, sustained improvements in functional status,work productivity, and HRQoL in participants with narcolepsy and OSA for up to 52 weeks.
EAEs associated with long-term solriamfetol treatment included headache,
nausea, nasopharyngitis,insomnia,dry-mouth,anxiety, decreased appetite
and upper respiratory tract infection and were similar between participants with
narcolepsy and those with OSA.
Comments